Tirzepatide (100 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tirzepatide (research code LY3298176) is a single-molecule dual incretin agonist studied for its combined activity at the GLP-1 and GIP receptors. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 100 mg vial, adding 5.0 mL of bacteriostatic water yields a concentration of 20 mg/mL (20,000 mcg/mL). At that concentration, every 0.05 mL drawn on a U-100 insulin syringe equals 5 units and delivers 1 mg of material, so a 5 mg dose corresponds to a 0.25 mL (25-unit) draw. Because the published step sizes increment by 2.5 mg, several draws land on half-unit graduations — these are flagged in the tables below.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation used in the clinical program, where weekly amounts were stepped up roughly every four weeks to manage gastrointestinal tolerability before reaching the maintenance band.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 5.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet — to limit foaming.
3. Swirl or roll gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide and generate foam.
4. The solution should be clear and colourless. Label the vial with the concentration (20 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule pushes past the 10 mg maintenance step toward the 12.5–15 mg ceiling tested in the trial program, where the highest cohorts recorded the largest average weight reductions. It escalates on the same four-week cadence but continues climbing once tolerability is established.

Supplies Needed

• Tirzepatide vials (100 mg): one vial covers a full 16-week gradual run (~25 mg used); the same vial covers most of a 16-week aggressive run (~45 mg used). A second vial gives headroom for extended maintenance.
• Insulin syringes (U-100, 1 mL): ~16 for a 16-week once-weekly schedule (one fresh syringe per draw); add spares for any aliquoting.
• Bacteriostatic water (10 mL): one bottle reconstitutes ~two 100 mg vials at 5 mL each.
• Alcohol swabs: a single 100-count box comfortably covers a 16-week schedule.

Protocol Overview

• Research goal: model metabolic and glycaemic regulation via simultaneous GLP-1 and GIP receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2.5–10 mg standard, escalating to 12.5–15 mg in aggressive arms.
• Fill: 100 mg lyophilized, reconstituted to 20 mg/mL with 5 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 2.5 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence, ideally the same day each week, for steady exposure modelling.
• Escalate only after tolerability is established at the prior step — the four-week holds exist to blunt gastrointestinal effects.
• The 5–10 mg band carries the bulk of the published efficacy signal; the 12.5–15 mg steps add incremental effect at the cost of tolerability.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (do not freeze) and use within about 28 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact across many draws.
• Watch the half-unit graduations on the 2.5 mg and 7.5 mg steps — round carefully when measuring.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tirzepatide Works

Tirzepatide is a synthetic 39–amino acid peptide engineered to act as a dual agonist at two incretin receptors at once: GLP-1 and GIP, both of which contribute to glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and reduced appetite signalling. A fatty-acid moiety extends its half-life to roughly five days, which is what supports once-weekly dosing in trials. The combined GLP-1/GIP activity is what distinguishes it from single GLP-1 agonists in the comparative literature, and it is the conceptual precursor to the triple agonists that followed.

Reported Benefits & Side Effects

Benefits observed in trials

• Marked HbA1c reductions across the Type 2 diabetes trial program.
• Substantial body-weight loss — on the order of 11 kg greater than a GLP-1 receptor agonist comparator over 26 weeks in one head-to-head.
• Improvements in lipid profiles and blood pressure reported in several studies.
• Dose-responsive weight outcomes, with the highest maintenance doses producing the largest reductions.

Side effects reported

• Dose-dependent gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — generally mild-to-moderate and most common during escalation.
• Occasional mild redness or irritation at subcutaneous administration sites.
• Effects typically transient and mitigated by slower titration.

Supporting Lifestyle Factors (Research Context)

• A balanced, calorie-appropriate diet, with reduced appetite often lowering intake in the study designs.
• Protein-forward nutrition to preserve lean mass during weight loss.
• Combined resistance and aerobic activity to support metabolic health.
• Adequate hydration, particularly given the potential for gastrointestinal effects.
• Sleep and stress management as standard adherence and recovery controls.

Injection Technique (Reference Only)

• Clean the vial stopper and site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily; rotate sites systematically (abdomen avoiding a ~2-inch radius around the navel, outer thighs, upper arms).
• Dispose of sharps in an approved container immediately after use.

References

Related Protocols